1. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of HIV/AIDS Prevention HIV testing among transgender persons funded by the Centers for Disease Control and Prevention in the United States, Puerto Rico, and U.S. Virgin Islands, 2008-2009 Nancy Habarta, Guoshen Wang, and Mesfin S. Mulatu July 26, 2012 Oral Poster Discussion : The Global Picture: Transgender Health and Rights

2. Key Findings Transgender (TG) testing events represent a small percentage of CDC-funded testing events, but have the highest HIV positivity by gender identity Majority of TG testing events (52%) conducted in non-healthcare facilities Nearly all (93%) TG testing events followed up with receipt of HIV test results

3. Key Findings: Among TG testing events  Gender 83% TG-MTF 17% TG-FTM  Race/Ethnicity Blacks (31%) and Hispanics (28%) accounted for majority  HIV positivity TG-MTF (2.9%) vs. TG-FTM (1.0%) Blacks (4.6%) and Hispanics (2.6%)  Risk behaviors TG-MTF were more likely than TG-FTM to report the majority of risk behaviors

4. Conclusions  TG testing events represent the smallest percentage of overall testing events but the highest percentage of HIV-positivity, highlighting the need to continue monitoring the epidemic and expanding prevention services for this special population.  HIV testing and positivity among TG varied by race, ethnicity, test facility, and TG identity. HIV prevention services need to be responsive to needs and characteristics of this population  Further improvements in surveillance and prevention data systems is critical to monitor our progress towards achieving our national goal of reducing HIV-related health disparities

5. For more information please contact Centers for Disease Control and Prevention 1600 Clifton Road NE, Atlanta, GA 30333 Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348 E-mail: cdcinfo@cdc.gov Web: http://www.cdc.gov The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. For more information please contact Centers for Disease Control and Prevention 1600 Clifton Road NE, Atlanta, GA 30333 Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348 E-mail: cdcinfo@cdc.gov Web: http://www.cdc.gov The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of HIV/AIDS Prevention Nancy Habarta, MPH Behavioral Scientist Division of HIV/AIDS Prevention National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease Control and Prevention 1600 Clifton Road NE, MS E-49 Atlanta, GA 30333 Phone: (404) 639-2034 E-mail: nhabarta@cdc.gov